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Abstract The e¡ects of LY294002 (LY29) and wortmannin
(WM), inhibitors of phosphatidylinositol 3-kinase (PI3K), on
monocyte chemoattractant protein-1 (MCP-1) expression by
human umbilical vein endothelial cells were investigated. Com-
plete inhibition of interleukin (IL)-1L-induced Akt phosphoryla-
tion occurred at 50 WM LY29 or 100 nM WM. At these con-
centrations, LY29, but not WM, signi¢cantly inhibited
constitutive and IL-1L-induced MCP-1 expression at both pro-
tein and mRNA levels. LY303511 (LY30), an inactive analogue
of LY29, also inhibited MCP-1 expression. LY29 and LY30
inhibited activation of nuclear factor-UB (NF-UB). These results
suggest that LY29 inhibits MCP-1 expression at least in part
via suppression of NF-UB, independent of PI3K, and the struc-
ture of LY29 and LY30 may be a novel template for develop-
ment of new anti-in£ammatory drugs.
5 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
LY294002 (LY29) and wortmannin (WM), speci¢c inhibi-
tors of phosphatidylinositol 3-kinase (PI3K), have been widely
used to examine the role of PI3K in cellular responses. LY29
and WM are structurally distinct compounds having working
concentrations of around 50 WM and 100 nM, respectively, for
cell-based assays [1^4]. Although the working concentration
of LY29 is about 500-fold higher than that of WM, LY29 is
widely used in cell biology as a speci¢c PI3K inhibitor because
it is much more stable in solution than WM [5].
In any studies with inhibitors, there is a possibility that
targets other than the desired one may be a¡ected. Indeed,
LY29 and WM can act via additional targets besides PI3K.
For example, while LY29 inhibited lipopolysaccharide-stimu-
lated nitric oxide production in Raw 264.7 macrophage cells,
WM was ine¡ective [6]. In contrast, only WM signi¢cantly
inhibited activation of mitogen-activated protein kinase in in-
terleukin (IL)-3-stimulated MC-9 mast cells [7]. However,
there has been no report on the di¡erential e¡ects of the
two inhibitors on cytokine production.
During our research into the intracellular signaling path-
ways of Porphyromonas gingivalis-induced monocyte chemo-
attractant protein-1 (MCP-1) production in endothelial cells,
we found that LY29, but not WM, potently inhibited P. gin-
givalis-induced MCP-1 mRNA expression, which led us to
conduct further experiments on the MCP-1-inhibitory e¡ect
of LY29 using IL-1L as an MCP-1 inducer. MCP-1, a CC
chemokine, plays important physiologic and pathogenic roles
by recruiting monocytes. In innate immunity, monocytes are
recruited from the blood to sites of infection by MCP-1. A
major role for MCP-1 in atherogenesis is well established. In
response to atherogenic stimulants including IL-1L, MCP-1 is
induced in endothelial cells and promotes the development of
atherosclerosis [8].
In this study, we report for the ¢rst time that the widely
used PI3K inhibitor, LY29, and its inactive analogue
LY303511 (LY30) inhibit IL-1L-stimulated MCP-1 produc-
tion by endothelial cells without involving PI3K.
2. Materials and methods
2.1. Chemicals and cell culture
LY29, LY30, and WM were purchased from Sigma (St. Louis, MO,
USA). LY29 and WM were dissolved in a 1:1 mixture of dimethyl-
sulfoxide and ethanol. LY30 was dissolved in water. Human recombi-
nant IL-1L was purchased from RpD Systems (Minneapolis, MN,
USA). Unless stated otherwise, all chemicals were from Sigma. Pri-
mary human umbilical vein endothelial cells (HUVEC) were pur-
chased from Clonetics (Walkersville, MD, USA) and used at passages
3^6. The cells were cultured in Ham’s F-12K medium (Life Technol-
ogies, Grand Island, NY, USA) supplemented with 10% fetal bovine
serum (Life Technologies), 25 Wg/ml endothelial cell growth supple-
ment, 100 Wg/ml heparin, and 50 Wg/ml gentamicin at 37‡C in 5%
CO2.
2.2. MCP-1 enzyme-linked immunosorbent assay (ELISA)
The HUVEC culture supernatants were collected, clari¢ed, and the
levels of MCP-1 were quanti¢ed using a commercial ELISA kit (RpD
Systems) according to the manufacturer’s directions.
2.3. Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from HUVEC and RT-PCR was done as
described previously [9]. The sequences of primers were 5P-CAGCCA-
GATGCAATCAATGC-3P, 5P-GTGGTCCATGGAATCCTGAA-3P
for MCP-1 (198 bp); 5P-GAGTCTTTCTCCAACGTGAGC-3P, 5P-
ACCTGGTACTTGAGTTTCCCA-3P for cyclooxygenase-1 (COX-1,
350 bp); 5P-TCAATGAGGAGACTTGCCTG-3P, 5P-GATGAG-
TTGTCATGTCCTGC-3P for IL-6 (260 bp); 5P-TTCAAATGA-
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GATTGTGGGAAAATTGCT-3P, 5P-AGTTCATCTCTGCCTGAG-
TATCTT-3P for COX-2 (305 bp); and 5P-AGCGGGAAATC-
GTGCGTG-3P, 5P-CAGGGTACATGGTGGTGCC-3P for L-actin
(300 bp).
2.4. Western blot for Akt
HUVEC in 6-well plates were scraped with 100 Wl of 1ULaemmli
sample bu¡er (4% sodium dodecyl sulfate (SDS), 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromophenol blue, and 0.125 M Tris^HCl,
pH 6.8). 20 Wl of each boiled sample was resolved by SDS^polyacryl-
amide gel electrophoresis (10%) and transferred to a polyvinylidene
di£uoride membrane (Bio-Rad, Hercules, CA, USA). The membrane
was probed with a 1:1000 dilution of rabbit anti-phospho-Akt poly-
clonal antibody (Cell Signaling Technology, Beverly, MA, USA) and
a 1:1500 dilution of horseradish peroxidase-conjugated goat anti-rab-
bit IgG secondary antibody (Cell Signaling Technology). Immunore-
active proteins were detected by enhanced chemiluminescence (Lumi-
GLO, Cell Signaling Technology). The same membrane was stripped
and reprobed with a 1:1000 dilution of anti-Akt (Cell Signaling Tech-
nology).
2.5. Gel shift assay for nuclear factor-UB (NF-UB)
Nuclear extracts were prepared from HUVEC according to the
method of Dignam et al. [10]. Protein concentrations of the nuclear
extracts were measured with DC Protein Assay Kit (Bio-Rad). Dou-
ble-stranded NF-UB-binding DNA probe (5P-AGTTGAGGG-
GACTTTCCCAGGC-3P) was purchased from Promega (Madison,
WI, USA), and end-labeled with [Q-32P]ATP and T4 polynucleotide
kinase. 15 Wg of nuclear extracts were incubated with 10 000 cpm of
probe in 20 Wl of reaction bu¡er containing 10 mM Tris^HCl (pH
7.6), 50 mM KCl, 1 mM EDTA, 5% glycerol, 1 mM dithiothreitol,
and 200 ng of poly(dIWdC) for 30 min at room temperature. Speci¢c
binding was controlled by competition with a 50-fold excess of cold
NF-UB probe or irrelevant cAMP response element-binding protein
(CREB) probe (Promega). The DNA-bound NF-UB proteins were
separated on 4% polyacrylamide gels. The gels were dried and sub-
jected to autoradiography.
3. Results and discussion
3.1. Activity of PI3K inhibitors
In order to con¢rm the PI3K-inhibiting activity of LY29
and WM at concentrations used in the present study, Akt
phosphorylation was examined by Western blotting. Akt is
phosphorylated by PI3K-generated phosphatidylinositol
3,4,5-trisphosphate and is thus sensitive to inhibition by
PI3K inhibitors [11]. As shown in Fig. 1, both 50 WM LY29
and 100 nM WM completely inhibited IL-1L-stimulated Akt
phosphorylation. At 50 WM, LY30, a compound structurally
related to LY29 but known to have no PI3K-inhibitory activ-
ity [2], did not inhibit IL-1L-stimulated Akt phosphorylation.
These data con¢rmed the ability of LY29 and WM to inhibit
PI3K activity and showed that LY30 does not inhibit PI3K
activity in our IL-1L-stimulated HUVEC model.
3.2. E¡ects of PI3K inhibitors on MCP-1 protein production
Modulation of MCP-1 protein production by LY29, LY30,
or WM was measured by ELISA. The level of MCP-1 in
HUVEC culture supernatants increased about 10-fold by
IL-1L stimulation (5 ng/ml). Treatment of cells with WM at
100 nM, which completely blocks PI3K activity, resulted in no
attenuation of IL-1L-stimulated MCP-1 production by HU-
VEC. In contrast, at 50 WM, LY29 decreased IL-1L-induced
MCP-1 production by about 80% (Fig. 2A). Not only LY29,
but also LY30 (50 WM) reduced MCP-1 production to a sim-
ilar extent. They also inhibited the basal MCP-1 production
by unstimulated cells. There has recently been a report that
LY29 and LY30 act as voltage-gated potassium (Kv) channel
blockers in the MIN6 insulinoma cell line [12]. This has been
the only report so far describing a PI3K-independent action of
both LY29 and LY30; however, a much higher dose of LY30
(500 WM) was needed to achieve comparableV90% inhibition
Fig. 1. Akt phosphorylation of IL-1L-, LY29-, WM-, or LY30-
treated HUVEC. 3U105 HUVEC were seeded in 6-well plates. After
2 days, the cells were pretreated with LY29 (50 WM), LY30 (50
WM), or WM (100 nM) for 30 min prior to stimulation with IL-1L
(10 ng/ml) for 30 min. Cell lysates were analyzed for Akt activation
by Western blot analysis of total and phosphorylated Akt using spe-
ci¢c antibodies. One of two experiments with similar results is
shown.
Fig. 2. MCP-1 production by HUVEC treated with IL-1L, LY29,
WM, or LY30. A: 6U104 HUVEC were seeded in 48-well plates.
After 1 day, the cells were pretreated with LY29 (50 WM), LY30 (50
WM), or WM (100 nM) for 30 min prior to stimulation with IL-1L
(5 ng/ml) in a ¢nal volume of 0.5 ml for 8 h. MCP-1 concentrations
of the culture supernatants were measured by ELISA. B: Dose re-
sponse of LY29 on MCP-1 production. HUVEC were pretreated
with various doses of LY29 for 30 min prior to stimulation with
IL-1L (5 ng/ml) in a ¢nal volume of 0.5 ml for 8 h. Data are the
meansRS.D. of a representative experiment performed in triplicate.
Similar results were obtained in two other experiments.
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of Kv currents than of LY29 (50 WM). LY29 was originally
developed from quercetin in search of more speci¢c PI3K
inhibitors and LY30 di¡ers from LY29 by a single atom sub-
stitution. Quercetin, a naturally occurring bio£avonoid, has
been shown to function as an anti-oxidant and anti-in£amma-
tory agent with little toxicity [13]. Quercetin inhibits IL-1-in-
duced MCP-1 expression in glomerular cells [14]. Therefore, it
is likely that the common structure of quercetin, LY29, and
LY30 inhibits MCP-1 production through a similar mecha-
nism. The inhibitory e¡ect of LY29 was dose-dependent (Fig.
2B). Attenuation of MCP-1 production by LY29 could be
observed following a dose as low as 10 WM. The inhibitory
e¡ect of LY29 and LY30 is not restricted to endothelial cells,
as they also inhibit IL-1L-stimulated MCP-1 production in
phorbol ester-di¡erentiated THP-1 macrophage cells (unpub-
lished data). Taken together, these results clearly showed that
LY29 inhibits MCP-1 production by endothelial cells, inde-
pendent of the PI3K-Akt pathway.
3.3. E¡ects of LY29 and LY30 on MCP-1 mRNA expression
To assess the inhibitory e¡ects of LY29 and LY30 on
MCP-1 production at the steady-state mRNA level, RT-
PCR analysis was carried out. The results of RT-PCR analy-
sis were consistent with those of the ELISA assays of MCP-1
protein levels (Fig. 3). LY29 and LY30, but not WM, inhib-
ited constitutive and IL-1L-induced MCP-1 mRNA expres-
sion. To rule out the possibility that the e¡ect of LY29 and
LY30 may be attributable to their general inhibitory e¡ect on
cellular activities, COX-1 mRNA expression, known to be
constitutive [15], was analyzed in parallel. COX-1 as well as
L-actin mRNA expression was not a¡ected by any treatment.
These results indicated that LY29 and LY30 down-regulate
MCP-1 production at the pre-translational level, and their
action is not due to their general cellular inhibitory e¡ects.
3.4. E¡ects of LY29 and LY30 on NF-UB activation
Since the MCP-1 inhibitory e¡ect of LY29 and LY30 could
be seen at the mRNA level and NF-UB is a critical transcrip-
tion factor for MCP-1 gene expression [16], we performed gel
shift assays to measure NF-UB activation. As shown in Fig. 4,
the DNA binding activity of NF-UB induced by IL-1L was
signi¢cantly inhibited by LY29 and LY30. The CREB probe
and cold competition demonstrated that the bands are NF-
UB-speci¢c. This prompted us to determine whether the ex-
pression of other NF-UB-dependent genes is also inhibited by
LY29 and LY30. As IL-6 and COX-2 genes, among IL-1-
induced endothelial genes, contain NF-UB binding sites in
their promoters and are controlled by NF-UB [17,18], we ex-
amined IL-6 and COX-2 mRNA expression by RT-PCR. In-
deed, the IL-1L-induced mRNA expression of both IL-6 and
COX-2 genes was signi¢cantly reduced by LY29 and LY30
(Fig. 5). These results are reminiscent of previous reports that
quercetin has the ability to attenuate activation of NF-UB
[14,19]. The molecular mechanisms for NF-UB suppression
by quercetin have been suggested to be related to the fact
that quercetin functions as an anti-oxidant or as a protein
kinase inhibitor [14]. Quercetin-derived LY29 and LY30
may accordingly share the same mechanisms. Further studies
are needed regarding how LY29 and LY30 inhibit NF-UB
activation leading to attenuated MCP-1 production. Mean-
while, our data are consistent with a report that the PI3K/
Akt pathway does not play a major role in the pro-in£amma-
Fig. 3. MCP-1 and COX-1 mRNA expression by HUVEC treated
with IL-1L, LY29, WM, or LY30. A: 3U105 HUVEC were seeded
in 6-well plates. After 2 days, the cells were pretreated with LY29
(50 WM), LY30 (50 WM), or WM (100 nM) for 30 min prior to
stimulation with IL-1L (5 ng/ml) for 4 h. Total RNA was extracted
and expression of MCP-1 and COX-1 mRNA was determined by
RT-PCR. B: Results are expressed as MCP-1/L-actin ratio by densi-
tometric analysis. One of three experiments with similar results is
shown.
Fig. 4. NF-UB activation in HUVEC treated with IL-1L, LY29,
WM, or LY30. 3U105 HUVEC were seeded in 6-well plates. After
2 days, the cells were pretreated with LY29 (50 WM), LY30 (50
WM), or WM (100 nM) for 30 min prior to stimulation with IL-1L
(5 ng/ml) for 4 h. Nuclear extracts were prepared and NF-UB acti-
vation was determined by gel shift assays. NF-UB speci¢city was
controlled with a 50-fold excess of cold NF-UB probe or irrelevant
CREB probe. One of three experiments with similar results is
shown.
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tory responses of endothelial cells to IL-1 [20]. Taken togeth-
er, our results suggest that LY29 and LY30 inhibit MCP-1
expression at least in part via suppression of NF-UB, indepen-
dent of PI3K. This represents the ¢rst report on the di¡er-
ential e¡ects of LY29 and WM on cytokine production.
The present study gives two suggestions. First, it is strongly
recommended that the e¡ects of the two structurally di¡erent
PI3K inhibitors WM and LY29 should be examined to reduce
the risk that the observed e¡ects of either PI3K inhibitor do
not result from inhibition of PI3K. Second, further studies on
the mechanisms of LY29 and LY30 mediating inhibition of
NF-UB activation and MCP-1 expression may shed more light
on pro-in£ammatory signaling pathways, and the structure of
quercetin-derived LY29 and LY30 may be a novel template
for development of new anti-in£ammatory drugs.
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Fig. 5. IL-6 and COX-2 mRNA expression by HUVEC treated with
IL-1L, LY29, WM, or LY30. A: 3U105 HUVEC were seeded in 6-
well plates. After 2 days, the cells were pretreated with LY29 (50
WM), LY30 (50 WM), or WM (100 nM) for 30 min prior to stimula-
tion with IL-1L (5 ng/ml) for 4 h. Total RNA was extracted and ex-
pression of IL-6 and COX-2 mRNA was determined by RT-PCR.
B: Results are expressed as IL-6 or COX-2/L-actin ratio by densito-
metric analysis. One of three experiments with similar results is
shown.
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